methoxyhydroxyphenylglycol has been researched along with Down Syndrome in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aerts, T; Coppus, AM; De Deyn, PP; Dekker, AD; Kremer, BP; Naudé, PJ; Van Dam, D; van Duijn, CM; Vermeiren, Y | 1 |
| Costa, AC; Scott-McKean, JJ | 1 |
| Mann, DM | 1 |
| Komatsu, H; Miyanomae, Y; Nishimura, A; Okano, S; Sawada, T; Takeuchi, Y | 1 |
| Cutler, NR; Haxby, JV; Kay, AD; Rapoport, SI; Riker, AK; Schapiro, MB | 1 |
| Haxby, JV; Kaufman, S; Kay, AD; May, C; Milstien, S; Rapoport, SI; Ryker, AK; Schapiro, MB | 1 |
| Chase, TN; Gordon, EK; Ng, LK | 1 |
1 review(s) available for methoxyhydroxyphenylglycol and Down Syndrome
| Article | Year |
|---|---|
The locus coeruleus and its possible role in ageing and degenerative disease of the human central nervous system.
Topics: Adult; Aged; Aging; Alzheimer Disease; Cerebral Palsy; Cytoskeleton; Dementia; Down Syndrome; Humans; Locus Coeruleus; Melanins; Methoxyhydroxyphenylglycol; Middle Aged; Parkinson Disease | 1983 |
6 other study(ies) available for methoxyhydroxyphenylglycol and Down Syndrome
| Article | Year |
|---|---|
Serum MHPG strongly predicts conversion to Alzheimer's disease in behaviorally characterized subjects with Down syndrome.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Disease Progression; Dopamine; Down Syndrome; Female; Humans; Male; Methoxyhydroxyphenylglycol; Middle Aged; Norepinephrine; Peptide Fragments | 2015 |
Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Down Syndrome; Electric Stimulation; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Hippocampus; In Vitro Techniques; Long-Term Synaptic Depression; Memantine; Methoxyhydroxyphenylglycol; Mice; Mice, Mutant Strains; N-Methylaspartate; Time Factors; Trisomy | 2011 |
Neuroleptic malignant syndrome-like state in a patient with Down syndrome and basal ganglia calcification.
Topics: Adolescent; Basal Ganglia Diseases; Calcinosis; Down Syndrome; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydroxyphenylglycol; Neuroleptic Malignant Syndrome; Rhabdomyolysis | 1992 |
Cerebrospinal fluid monoaminergic metabolites are elevated in adults with Down's syndrome.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Catecholamines; Down Syndrome; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydroxyphenylglycol; Middle Aged; Norepinephrine | 1987 |
Cerebrospinal fluid monoamines in Down's syndrome adults at different ages.
Topics: Adult; Age Factors; Amines; Biopterins; Catecholamines; Cognition; Dementia; Down Syndrome; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydroxyphenylglycol; Middle Aged; Neopterin; Norepinephrine | 1987 |
Norepinephrine metabolism in the central nervous system of man: studies using 3-methoxy-4-hydroxyphenylethylene glycol levels in cerebrospinal fluid.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Carbon Radioisotopes; Cerebrospinal Fluid; Child; Chromatography, Gas; Dihydroxyphenylalanine; Dopamine; Down Syndrome; Dystonia Musculorum Deformans; Female; Glycols; Homovanillic Acid; Humans; Huntington Disease; Hydroxyindoleacetic Acid; Male; Methoxyhydroxyphenylglycol; Methyltyrosines; Middle Aged; Norepinephrine; Parkinson Disease; Picolinic Acids; Probenecid; Serotonin; Spinal Cord Diseases; Time Factors | 1973 |